Evidence map›Paper›PMID 27692155›Full record

ArticleRespiratory medicine2016

Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Sean J Callahan, Meng Xia, Susan Murray, Kevin R Flaherty

Open access · bronzeAbstract read
In one paragraph

Article in Respiratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting the AXL Receptor in Combating Smoking-related Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2021
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sean J CallahanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Virginia Health System, P.O. Box 800546, Charlottesville, VA 22908, USA. Electronic address: sjc4z@virginia.edu.
Meng XiaDepartment of Biostatistics, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.
Susan MurrayDepartment of Biostatistics, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
University of Michigan · USMichigan Medicine · USUniversity of Virginia Health System · US

Funding

Longitudinal, computer assisted analysis in IPFR01HL091743 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 2008 to 2011
$1.6M
Forging a road to personalized medicine in interstitial lung diseasesK24HL111316 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 2012 to 2017
$909k
NHLBI NIH HHS K24 HL111316NHLBI NIH HHS R01 HL091743
6 · The paper itself

Abstract

backgroundA group of patients with idiopathic pulmonary fibrosis (IPF) presents with disease affecting one lung markedly more than the other. At this time, it is unclear how this population differs from those who present with more symmetric disease. We sought to explain the characteristics of the asymmetric group and how their disease progresses.

methodsIn this retrospective case-control study we accessed an interstitial lung disease (ILD) database and identified 14 asymmetric IPF cases via high-resolution computed tomography (HRCT) scoring of each lung lobe's disease severity. We identified 28 symmetric IPF controls from the same database using the same methods, and compared the clinical features of each group.

resultsPatients with asymmetric disease exhibited similar demographics as those in the general IPF population; they were predominantly male (64%), elderly (69 years old), and used tobacco (57%). We found a trend toward significantly increased all-cause mortality in the case population two years following diagnosis (p = 0.089). Pulmonary function tests were significantly lower in the case group at the time of diagnosis, then both groups experienced gradual decline. We found no statistically significant differences in number of IPF exacerbations (cases 43%, controls 39%, p = 0.824) and gastro-esophageal reflux (both groups 50%).

conclusionPatients with asymmetric IPF resemble patients in the general IPF population but may have a lower overall survival rate. Further systemic factors may be studied to identify reasons for disease asymmetry and clinical decline in this population.

Indexed as

AgedBiopsyCarbon MonoxideCase-Control StudiesDisease ProgressionFemaleForced Expiratory VolumeHumansIdiopathic Pulmonary FibrosisLungLung Diseases, InterstitialMaleMiddle AgedPrevalencePulmonary Diffusing CapacityRespiratory Function TestsCarbon MonoxideAsymmetricFibrosisHigh resolution CTHoneycombingIPFSurgical lung biopsy

Identifiers

PMID27692155
PMCPMC5074687
OpenAlexW2507925328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.